Abstract: The present invention relates to improvements made in the blister advancement mechanism of dry powder inhaler devices. A dry powder inhaler device mechanism comprising an actuator plate and a transmission wheel is provided.

Abstract: The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.

Abstract: The present invention relates to a formulation comprising Propolis, Ginseng root and Zingiber officinale extracts to be used in the treatment, prevention of various respiratory diseases or alleviation and/or elimination of symptoms thereof and a method for preparing said formulation.

Abstract: The present invention is related to a formulation comprising Hedera helix, Pelargonium sidoides, and Zingiber officinale extracts to be used in the treatment, prevention of various respiratory diseases or alleviation and/or elimination of symptoms thereof and a method for preparing said formulation.

Abstract: The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.

Abstract: The present invention relates to a dry powder inhaler device comprising a body having a guide surface formed on an inner surface thereof, a trigger having a socket with a shape complementing the guide surface, and a spring, characterized by comprising at least one retaining element (8) positioned on the inner surface (1) of the body diagonally across the spring (6) to enable the trigger (5) to perform a stable axial displacement and a mechanism check or quality control to be made as one of the parts of the device (7) body is not closed or assembled yet.

Abstract: The present invention relates to a formulation comprising extracts of Hedera helix, Pelargonium sidoides and Echinacea purpurea for use in the treatment, prevention of, or the alleviation and/or elimination of the symptoms of various respiratory tract diseases, as well as to a method for preparing this formulation.

Abstract: The present invention relates to a formulation comprising extracts of Hedera helix and Pelargonium sidoides for use in the treatment, prevention of, or the alleviation and/or elimination of the symptoms of various respiratory tract diseases, as well as a method for preparing this formulation.

Abstract: The present invention relates to a novel pharmaceutical composition comprising zaltoprofen or a pharmaceutically acceptable salt thereof in combination with muscle relaxants with anti-inflammatory, analgesic and myorelaxant activity.

Abstract: This invention is a novel pharmaceutical composition comprising sofosbuvir and ribavirin as active agents with at least one pharmaceutically acceptable excipient, wherein at least one of the active agents is in the form of controlled release, for use in the treatment of hepatitis C virus infections, chronic hepatitis C, hepatocellular carcinoma or patients with end-stage liver disease awaiting liver transplantation.

Abstract: This invention is a novel pharmaceutical composition comprising loxoprofen or a pharmaceutically acceptable salt thereof in combination with gamma-aminobutiric acid receptor agonist or a pharmaceutically acceptable salt thereof with anti-inflammatory, analgesic and myorelaxant activity.

Abstract: This invention is a novel modified release pharmaceutical composition comprising sofosbuvir and ribavirin and at least one pharmaceutically acceptable excipient for use in the treatment of hepatitis C virus infections, chronic hepatitis C (CHC), hepatocellular carcinoma or patients with end-stage liver disease awaiting liver transplantation.

Abstract: This invention is a novel pharmaceutical composition comprising sofosbuvir and ribavirin and at least one pharmaceutically acceptable excipient for use in the treatment of hepatitis C virus infections, chronic hepatitis C (CHC), hepatocellular carcinoma or patients with end-stage liver disease awaiting liver transplantation.

Abstract: This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases. More particulary, the invention relates to pharmaceutical composition for inhalation further comprising a ternary component. In addition, the present invention relates to novel pharmaceutical composition for inhalation based on combinations of long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them.

Abstract: The present invention relates to a pharmaceutical combination of flurbiprofen or a pharmaceutically acceptable salt thereof, glucosamine or a pharmaceutically acceptable salt thereof and capsaicin or a pharmaceutically acceptable salt thereof. Particularly, the present invention relates to a pharmaceutical combination for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders, especially with osteoarthritis and rheumatoid arthritis.

Abstract: The present invention relates to a formulation comprising extracts of Hedera helix, Pelargonium sidoides and Echinacea purpurea for use in the treatment, prevention of or the alleviation and/or elimination of the symptoms of various respiratory tract diseases, as well as to a method for preparing this formulation.

Abstract: The present invention relates to a formulation comprising Propolis, Ginseng root and Zingiber officinale extracts to be used in the treatment, prevention of various respiratory diseases or alleviation and/or elimination of symptoms thereof and a method for preparing said formulation.

Abstract: The present invention relates to a formulation comprising extracts of Hedera helix and Pelargonium sidoides for use in the treatment, prevention of, or the alleviation and/or elimination of the symptoms of various respiratory tract diseases, as well as a method for preparing this formulation.

Abstract: The present invention is related to a formulation comprising Hedera helix, Pelargonium sidoides, and Zingiber officinale extracts to be used in the treatment, prevention of various respiratory diseases or alleviation and/or elimination of symptoms thereof and a method for preparing said formulation.

Abstract: Modified release oral pharmaceutical compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof in the form of a bilayer tablet and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.